Endologix® Inc. (Nasdaq: ELGX) (“Endologix” or the “Company”), a developer and marketer of innovative treatments for aortic disorders, today announced that a correction notice has been issued for the Ovation iX system, that identifies the root cause of polymer leaks. This voluntary action has been c

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/endologix-issues-correction-notice-ovation-ix-abdominal-stent-graft-system